Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Lymphocytic Leukemia: early-phase trial registry
9 of 25 indexed Acute Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 9 currently recruiting · #652 of 28,707 conditions by registered trial count
Acute Lymphocytic Leukemia: 25 US clinical trials tracked, 9 recruiting.
Acute Lymphocytic Leukemia is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 2 of these trials.
Enrollment posture brief
Registry condition acute-lymphocytic-leukemia
OPEN 9 | RECR 36% | LATE 0 | EARLY 22 | RANK #652 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Cannabis (36% recruiting · 25 trials)
Acute Lymphocytic Leukemia lists 9 open slots (36% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Lymphocytic Leukemia is recruiting below its size-band peers.
9 of 25 indexed trials (36%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Lymphocytic Leukemia trials is spread across many organizations.
Washington University School of Medicine accounts for 2 of 25 trials (8%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 25 trials that report a genuine target (sentinel values excluded). 21 of those (84%) plan for fewer than 100 participants.
-
Acute Lymphocytic Leukemia research is mostly interventional.
23 interventional and 2 observational studies make up this index (92% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
NCT01890486
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05442515
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT01853631
Pilot Imaging Study of Leukemia
University of Oklahoma
NCT03633955
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05805605
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Leland Metheny
NCT03104491
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT06904482
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
NCT05044039
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03674411
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
NCT01430390
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Baylor College of Medicine
NCT00586391
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03755414
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT00674479
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT00349596
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00145626
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
University of California, San Francisco
NCT00516152
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Tara Lin
NCT02914977
Experimental Bone Marrow Transplant Protocol
National Heart, Lung, and Blood Institute (NHLBI)
NCT00061581
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
ViaCell
NCT00089596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Lymphocytic Leukemia page
25 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Acute Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Acute Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphocytic Leukemia condition card totals 25 registered trials; most-linked intervention Fludarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.